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Abstract
Cachexia is deﬁned as an excessive, involuntary loss of fat and lean tissue.
We tested the validity of the Lewis lung carcinoma (LLC) as a model of
cancer cachexia and examined its effect on the two major lean tissue compo-
nents, skeletal muscle and bone. LLC cells (0.75 9 10
6) were injected into
the left thigh of C57BL/6 mice. Control mice received an equal volume
injection of growth media. Tumors were observed in all LLC-injected ani-
mals 21 and 25 days post inoculation. LLC-injected animals showed signiﬁ-
cant reductions in fat and lean mass despite having the same average daily
caloric intake as media-treated mice. Global bone mineral density (BMD)
had fallen by 5% and 6% in the LLC animals at 21 and 25 days, respec-
tively, compared to a BMD increase of 5% in the 25-day media-treated ani-
mals. Extensor digitorum longus (EDL) muscles (isolated from the
noninjected hindlimb) showed earlier and quantitatively greater losses in
mass, physiological cross-sectional area (pCSA), and tetanic force compared
to soleus muscles from the same hindlimb. By the 25th day post-LLC inocu-
lation, EDL force/pCSA was reduced by 19% versus media treatment. This
loss in speciﬁc force was not trivial as it accounted for about one-third of
the reduction in EDL absolute force at this time point. Muscle strips dis-
sected from the diaphragm of LLC mice also exhibited signiﬁcant reductions
in force/pCSA at day 25. We conclude that LLC is a valid model of cachexia
that induces rapid losses in global BMD and in limb and respiratory muscle
function.
Introduction
Several forms of cancer, and particularly those of the lung
and viscera, are associated with a profound loss of fat and
lean tissue, a condition known as cachexia. Skeletal mus-
cle, which represents the largest lean tissue component of
the body, may be reduced to 25% of its normal mass in
severe cachexia while nonmuscle protein is relatively
spared (Fearon 1992). Cachexia is present to some degree
in approximately 50% of cancer deaths (Inagaki et al.
1974). Of these fatalities, about half can be directly attrib-
uted to the immobility and respiratory muscle insufﬁ-
ciency that result from extensive skeletal muscle wasting
(Inagaki et al. 1974; Fearon 1992).
Bone, the second largest lean tissue compartment, also
appears to be impacted by cachexia. Lung cancer
patients who had lost 30% of their body mass showed
signiﬁcantly lower mineral content than their healthy-
matched peers (Fearon 1992). However, bone loss in
cachexia has been studied much less than muscle wast-
ing despite the fact that cachexia-induced deterioration
of the skeletal system could have critical long-term
health consequences for cancer survivors. Kandarian
(2008) has proposed that muscle and bone mass may
be regulated in tandem during cachexia because a num-
ber of the signaling pathways that induce muscle wast-
ing are also known to promote bone loss. Thus,
interactions between muscle and bone may represent a
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unexplored, aspect of cachexia.
A better understanding of how cachexia impacts the
musculoskeletal system requires the development and
characterization of preclinical animal models for use in
mechanistic studies. A number of tumor models have
been used to induce skeletal muscle loss in laboratory
rodents. However, many of these models have not been
rigorously evaluated as models of cachexia. Nor is it clear
whether they impact the skeletal system. Finally, various
approaches used to quantify the effects of cachexia have
produced somewhat contradictory ﬁndings that warrant
further investigation.
As an example of the later, a number of functional
studies have concluded that during cachexia, muscle force
declines in direct proportion to losses in muscle mass or
ﬁber size (Gorselink et al. 2006; Aulino et al. 2010;
Murphy et al. 2011). This suggests that during cachexia,
muscle cells show a reduction in their cross-sectional area
but are otherwise normal. In contrast, molecular and
histological approaches have revealed intracellular pertur-
bations to muscles from cachexic animals that would be
expected to detrimentally affect force measurements at
tendons. These include disproportionate losses in the
motor protein myosin and in the force-transmitting pro-
tein dystrophin (Acharyya et al. 2004, 2005) and an
extensive disarrangement of the myoﬁlament lattice (Auli-
no et al. 2010). In addition, many of the molecules that
signal muscle wasting in cachexia, such as nuclear factor
of kappa B (Wyke et al. 2004), TNF-a (Llovera et al.
1998a), and reactive oxygen intermediates (Buck and
Chojkier 1996), have acute and/or persistent detrimental
effects on cellular mechanisms of muscle contraction
(Andrade et al. 1998; Cai et al. 2004; Hardin et al. 2008;
Prochniewicz et al. 2008).
To address these issues, we evaluated caloric intake,
global lean and fat mass, whole-body bone mineral den-
sity (BMD), and the functional properties of skeletal
muscles of tumor-bearing mice. Tumors were induced
using the Lewis lung carcinoma (LLC), a well-estab-
lished tumor model (Mayo 1972). Injection of LLC cells
into a hindlimb muscle has been used previously in
studies of body composition, muscle atrophy, muscle
protein turnover, and muscle function (Llovera et al.
1998b; Busquets et al. 2004; Nicholson et al. 2006;
Argiles et al. 2008; Murphy et al. 2011). In preliminary
work, we found intramuscular injection of LLC cells to
be a more reliable and robust method of inducing
tumor growth compared to subcutaneous injection
(Azouz et al. 2008). We therefore injected LLC cells into
one hindlimb of C57BL6 mice and several weeks later
examined, (1) changes in body composition and BMD
using small-animal dual energy X-ray absorptiometry
(DXA), (2) ex vivo functional properties of representa-
tive oxidative and glycolytic limb muscles from the con-
tralateral noninjected hindlimb, and (3) function of the
critically important diaphragm (DIA). To identify any
temporal effects of tumor burden, all variables were
assessed after tumors were well established and again
after several days of additional tumor growth.
Methods
Animal care procedures
All procedures involving animals were approved by the
IACUC at the Forsyth Institute, Cambridge, MA. Male
C57BL6 mice were obtained from Charles River Laborato-
ries. All mice were 56 days of age upon arrival. The ani-
mal facility where the animals were housed was
maintained at 23°C with a 12:12-h light-dark cycle.
Throughout the study, mice had ad libitum access to tap
water and a standard rodent diet (5053 PicoLab rodent
diet 20, LabDiet, St. Louis, MO). Chow mass was deter-
mined at the start and conclusion of each study and an
average caloric intake for each animal calculated by divid-
ing this value by the number of days in the experiment.
Lewis lung carcinoma
Lewis lung carcinoma cells (# CRL-1642) were purchased
from American Type Culture Collection, Manassas, VA.
Cells were cultured in Dulbecco’s Modiﬁed Eagle’s Med-
ium (DMEM) containing 10% fetal bovine serum, 1% of
100 U/mL penicillin, and 100 lg/mL streptomycin and
were passaged every 3–4 days. For injections, cells were
diluted in DMEM at a concentration of 3 9 10
6 cells/mL.
Experimental design
Mice were assigned to a media treatment group or an LLC
treatment group. Assignment to media and LLC treatments
was balanced in order to minimize group differences in ini-
tial body mass. When they were between 61 and 66 days old,
mice were anesthetized with a xylazine/ketamine cocktail
(0.1 mg xylazine/kg; 0.02 mg ketamine/kg) and the dorsal
surface of the left limb shaved. A 250-ll bolus of growth
media containing 7.5 9 10
5 LLC cells was injected into
the left thigh of mice making up the LLC-treated group.
Animals in the media-treated group received a similar
injection containing growth media only. After determina-
tion of body composition (see below), the animals were
returned to their individual cages and periodically moni-
tored as they recovered from the anesthesia. Animals were
studied again either 21 or 25 days post inoculation. These
time points were chosen so that we could, (1) compare
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ied tumor-bearing animals out to 21–22 days (Gorselink
et al. 2006; Aulino et al. 2010), and (2) provide several
days of additional tumor growth (Mayo 1972) in order to
observe time-related effects of tumor burden.
Dual energy X-ray absorptiometry
On the day of study, mice were lightly anesthetized
with an intraperitoneal injection of sodium pentobarbi-
tal. Body composition and global (whole body minus
the head) BMD were determined in vivo using a Lunar
PIXImus small-animal DXA scanner (Lunar PIXImus2,
software version 1.4X, GE Medical Systems Inc., Wauke-
sha, WI). Lean mass was determined by subtracting fat
mass from total tissue mass. To assess the contribution
of the tumor to body composition, scans were repeated
under the following conditions and the results were
compared: (1) excluding the tumor from the scan area
and (2) excising the tumor after sacriﬁce and rescan-
ning the animal. To exclude the tumor from the scan
an oval-shaped exclusion area was placed over the visi-
ble edges of the tumor. Using anatomical landmarks, a
similar region was excluded in the baseline scans.
Muscle function
After the posttreatment DXA measurements, animals
were administered additional pentobarbital (i.p.) until
they reached a surgical plane. The extensor digitorum
longus (EDL) and soleus (SOL) from the right limb
were then excised. SOL and EDL muscles were obtained
from the right hindlimb in order to avoid any physical
effect that the tumor mass may have had on the muscles
of the left hindlimb. After limb muscle dissection, the
DIA was excised. We focused only on these particular
muscles because they have the following qualities: (1)
taken together, they provide a wide range in ﬁber-type
composition and metabolic proﬁle, (2) they all have a
relatively small radius for oxygen diffusion, which
allowed us to study them ex vivo, and (3) they cover a
range of physiological functions in that they represent a
hindlimb extensor, a hindlimb ﬂexor, and a respiratory
muscle.
Muscles were pinned out at a slightly stretched length
on a Sylgaar base in a small dish containing a modiﬁed
bicarbonate buffer (composition, in mmol/L: 137 NaCl,
11 glucose, 5 KCl, 1.25 CaCl2, 1 MgSO4, 1 NaH2PO4,
24 NaHCO3, 0.025 tubocurarine chloride). The buffer
was equilibrated with 95% O2 and 5% CO2. Small mus-
cle strips, which included the central tendon and rib,
were dissected from the costal DIA. Silk suture was used
to suspended intact SOL and EDL muscles and DIA
strips vertically in a tissue bath between a hook and an
isometric force transducer (model 60-2996, Harvard
Apparatus, Holliston, MA) as described previously (Wid-
rick et al. 2011). The hook could be translated by a
micrometer allowing ﬁne changes in muscle length. The
bath contained bicarbonate buffer that was continuously
aerated with 95% O2 and 5% CO2 and maintained at
35°C.
Muscles were stimulated using 200-lsec square wave
pulses delivered to platinum electrodes ﬂanking the
muscle. A personal computer, data acquisition board
(model 6229; National Instruments, Austin, TX), and
custom program written in LabView (National Instru-
ments) were used to control the output of a biphasic
constant current muscle stimulator (model 701; Aurora
Scientiﬁc Inc., Aurora, ON, Canada) while simulta-
neously recording muscle force to disk (1000 Hz). Stim-
ulation current and muscle length were adjusted to
maximize tetanic force during a 300 Hz, 150 msec stim-
ulus train for EDL muscles, a 200 Hz, 500 msec train
for SOL muscles, and a 200 Hz, 300 msec train for
DIA strips. The length of the muscle giving maximum
force was measured with digital calipers and recorded
as optimal length (Lo). To minimize fatigue, at least 3
minutes separated all contractions. Muscle physiological
cross-sectional area (pCSA) was calculated by dividing
muscle mass by the product of ﬁber length and muscle
density. Fiber length was calculated using the ﬁber
length to Lo ratios (0.71 for SOL, 0.44 for EDL, 1.00
for DIA) available in the literature (Brooks and Faulk-
ner 1988; Stevens and Faulkner 2000). Muscle density
was taken as 1.06 g/cm
3 (Mendez and Keys 1960). Spe-
ciﬁc force, or stress, was deﬁned as peak tetanic force
divided by pCSA. Muscle force and stress were
expressed in SI units (newtons and pascals, respec-
tively).
Statistical analysis
Data are presented as mean  SE. For muscle variables,
the four treatment conditions were analyzed by one-way
analyses of variance (ANOVA). In cases where pre- and
posttreatment data were obtained (body composition,
bone), we conducted a repeated measures ANOVA (treat-
ment 9 time) on the raw data with a follow-up one-way
ANOVA on the change in each variable (postvalue minus
prevalue) over time. In the case of signiﬁcant main effects
(ANOVA) or treatment 9 time interactions (repeated
measures ANOVA), differences between means were iden-
tiﬁed using the Bonferroni post hoc procedure. All statis-
tical analysis were performed using GraphPad Prism 6
(GraphPad Software Inc., La Jolla, CA) at an alpha error
rate of P < 0.05.
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Tumor mass
All LLC-injected mice developed a semisolid tumor in the
upper left hindlimb. Tumor masses reached an average of
3.9  0.4 g (N = 13) at the 21-day time point and
5.7  0.3 g (N = 15) after 25 days.
Tumor-free body mass and caloric intake
Tumor-free body mass increased for the media-treated
animals but declined for the LLC-treated animals
(Fig. 1A). The 21-day and the 25-day LLC-treated groups
showed similar changes in body mass (1.8  0.4 and
1.4  0.2 g, respectively, P > 0.999). The opposing
changes in the tumor-free mass of the media- versus
LLC-treated mice occurred even though average daily
chow consumption and caloric intake was similar between
groups (Fig. 1B).
Body composition
No change in lean mass was detected when determining
body composition with the tumor present and included
in the scan (data not shown). This is due to the composi-
tion of the tumor itself which is composed of lean mass,
thereby obscuring loss of total body lean mass. When the
tumor was excluded from the scan, lean and fat mass
were unchanged in 21-day media-treated mice, but
declined by 2.5 and 1.9 g, respectively, in their LLC-trea-
ted counterparts (Fig. 2). At the 25-day time point,
media-treated mice showed an increase in lean mass with
no change in fat mass, whereas lean and fat mass fell 3.6
and 2.1 g, respectively, in the LLC-treated animals. There
were no statistically signiﬁcantly differences between LLC
21-day versus LLC 25-day losses in either fat mass
(P > 0.999) or lean mass (P = 0.446), that is, an addi-
tional 4 days of tumor growth did not effect changes in
the body composition in the LLC animals. Similar results
were obtained from a subset of animals in which the
tumor was excised after sacriﬁce but prior to the DXA
scan (data not shown).
Bone mineral density
Bone mineral density was reduced by the LLC model.
After 21 days of LLC treatment, BMD had fallen by 5%
from the pretreatment value (Fig. 3). Extending LLC treat-
ment an additional 4 days resulted in a 6% reduction in
BMD, a change that was not statistically signiﬁcantly dif-
ferent from the LLC 21-day response. In contrast, media-
treated mice showed either no change (21 days), or an
increase (25 days), in BMD over the course of the study.
Limb muscle mass, pCSA, and tetanic force
Twenty-one days of LLC treatment had no effect on SOL
muscle mass, pCSA (0.854  0.024 mm
2 vs. 0.787 
0.020 mm
2 for media- and LLC-treated, respectively), or
tetanic force (Fig. 4). Four additional days of exposure to
LLC reduced the mass, pCSA (0.843  0.016 mm
2 vs.
0.699  0.019 mm
2, P < 0.001), and tetanic force of this
muscle by 17–20%. The EDL was more sensitive to LLC.
By the 21-day time point, the EDL has already experi-
enced a 18% loss in mass, a 14% reduction in pCSA
(1.67  0.05 mm
2 vs. 1.43  0.03 mm
2,P< 0.001), and
a 21% decline in tetanic force (Fig. 5). Unlike the changes
in body mass, body composition, and BMD described
above, 4 days of additional tumor growth resulted in fur-
ther reductions in EDL mass, pCSA, and tetanic force
(LLC 25-day values all signiﬁcantly different from the
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mass was reduced by 30%, physiological cross sectional
by 29% (1.70  0.03 mm
2 vs. 1.21  0.03 mm
2,
P < 0.001), and tetanic force by 43% in comparison to
the 25-day media-treated values.
Limb and respiratory muscle-speciﬁc force
At 21 days post-LLC inoculation, speciﬁc force was simi-
lar to media-treated values for all three muscles studied
(Fig. 6). However, extending exposure to LLC to 25 days
resulted in a 19% reduction in the speciﬁc force of both
the EDL and the DIA.
Discussion
The LLC is a commonly used method of inducing tumor
growth in laboratory mice. The cell line arose as a sponta-
neous carcinoma in the lung of a C57BL mouse in the
early 1950s (see Mayo 1972). The LLC model is fre-
quently used to study alterations in body composition,
B
M
D
,
g
/
c
m
2
0.000
0.035
0.040
0.045
0.050
0.002 < 0.001 < 0.001
pre  21d    pre  21d     pre  25d    pre  25d
M            L            M             L
Figure 3. Bone mineral density (BMD) of media-treated (M) and
Lewis lung carcinoma-treated (L) mice. Repeated measures ANOVA
revealed a signiﬁcant interaction between treatment and time
(P < 0.001). Differences between means were evaluated by the
Bonferroni post hoc procedure with horizontal lines connecting
means that are signiﬁcantly different (P-values above lines). Number
of animals same as in Figure 2.
S
O
L
m
a
s
s
,
m
g
ML ML
0
2
4
6
8
10
0.028
< 0.001
S
O
L
f
o
r
c
e
,
m
N
ML ML
0
50
100
150
200
250
21 d 25 d 21 d 25 d
0.001
0.016
AB
Figure 4. Properties of soleus (SOL) muscles from media-treated
(M) and Lewis lung carcinoma-treated (L) mice. (A) Muscle mass.
(B) Tetanic force. ANOVA revealed signiﬁcant main effects for SOL
mass (P < 0.001) and SOL force (P < 0.001). Differences between
means were evaluated by the Bonferroni post hoc procedure with
horizontal lines connecting means that are signiﬁcantly different
(P-values above lines). Number of muscles: 9 M and 11 L at
21 days; 9 M and 9 L at 25 days.
E
D
L
 
m
a
s
s
,
 
m
N
ML ML
0
2
4
6
8
10
12
21 d         25 d
0.005
< 0.001 < 0.001
E
D
L
 
f
o
r
c
e
,
 
m
N
ML ML
0
100
200
300
400
500
21 d         25 d
< 0.001 < 0.001
< 0.001 AB
Figure 5. Properties of extensor digitorum longus (EDL) muscles
from media-treated (M) and Lewis lung carcinoma-treated (L) mice.
(A) Muscle mass. (B) Tetanic force. ANOVA revealed signiﬁcant
main effects for EDL mass (P < 0.001) and EDL force (P < 0.001).
Differences between means were evaluated by the Bonferroni post
hoc procedure with horizontal lines connecting means that are
signiﬁcantly different (P-values above lines). Number of muscles:
11 M and 12 L at 21 days; 9 M and 10 L at 25 days.
f
a
t
m
a
s
s
,
g
M
21
L
21
M
25
L
25
0
1
2
3
4
        21 d                  25 d
< 0.001 < 0.001
l
e
a
n
m
a
s
s
,
g
0
10
12
14
16
18
20
22
< 0.001 < 0.001 < 0.001
pre  21d    pre  21d     pre  25d    pre  25d
M            L            M             L
Figure 2. Body composition of media- (M) and Lewis lung
carcinoma-(L) treated mice. Repeated measures ANOVA revealed a
signiﬁcant interaction between treatment and time for lean
(P < 0.001) and fat (P < 0.001) masses. Differences between
pre- and postmeans were evaluated by the Bonferroni post hoc
procedure with horizontal lines connecting means that are
signiﬁcantly different (P-values above lines). N = 5 M and 10 L mice
at 21 days; 11 M and 9 L mice at 25 days.
ª 2013 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
the American Physiological Society and The Physiological Society.
2013 | Vol. 1 | Iss. 6 | e00144
Page 5
E. Choi et al. Muscle and Bone Loss in Cancer Cachexiaprotein turnover, muscle mass, and muscle function in
cachexia (Llovera et al. 1998b; Busquets et al. 2004; Nich-
olson et al. 2006; Argiles et al. 2008; Benny Klimek et al.
2010; Murphy et al. 2011).
The time course of LLC tumor growth and ﬁnal tumor
mass observed in this study are similar to earlier work
using this model. Mayo (1972) implanted LLC tumor
fragments subcutaneously in over 200 mice and reported
average tumor masses of 4.6 and 6.4 g at days 20 and 24,
respectively, with a median survival time of 25 days. The
tumor masses we observed in this study, 3.9 and 5.7 g at
21 and 25 days, respectively, are somewhat less than those
reported by Mayo and may reﬂect a delay in tumor for-
mation when using an injected cell bolus versus the
implantation of established tumor fragments. Consistent
with this idea, we observed no mortality at 25 days post-
tumor injection.
To conﬁrm that the LLC model is a valid model of
cachexia, we quantiﬁed lean and fat compartments using
small-animal DXA. Our results indicate that LLC treat-
ment not only prevented the normal growth of the young
mice studied here, but resulted in signiﬁcant losses in
their lean and fat tissue masses. These observed losses of
lean and fat tissue could not be attributed to a reduced
caloric intake by the LLC-treated animals. In fact, if chow
consumption was calculated on a tumor-free body mass
or lean mass basis, the caloric intake of the tumor-bearing
mice would have exceeded that of their media-treated
counterparts. Therefore, LLC-induced reductions in lean
and fat tissue mass could not be attributed to reduced
calorie intake, ﬁndings which validate the use of LLC as
an experimental model of cachexia.
Bone loss was detectable at 21 days in the LLC-treated
animals and became more pronounced at 25 days. This
reduction in global BMD reached 5–6% in LLC animals,
a difference that is even more noteworthy when one con-
siders that in our growing animals, BMD increased by an
average of 5% in the media-treated animals (day 25). We
cannot exclude the possibility that an element of focal
bone loss from the injected hindlimb side contributed to
the total bone loss reported in this study. Alternative
methods, such as microCT, may be required to identify
small side-to-side hindlimb regional differences in bone
density. However, it seems unlikely that focal bone loss
near the injection site can entirely explain the 5–6% total
body bone loss observed here.
The magnitude of this change in whole-body BMD
approximates that observed for mice subjected to 21 days
of hindlimb suspension (Spatz et al. 2013) or studied
after 2 months of ovariectomy (Kim et al. 2013). This
rapid and severe bone loss would be associated with
increased fracture risk and is therefore clinically relevant.
The mechanisms of bone loss in this model are unknown,
but are not due to bony metastasis and may be multifac-
torial in nature. Previously, mineral content was reported
to be signiﬁcantly lower in cancer patients compared with
matched controls (Fearon 1992), but to our knowledge,
this is the ﬁrst report of reduced BMD in an animal
model of cancer cachexia. The present work indicates that
the LLC mouse may be an appropriate model for use in
preclinical studies designed to address this underre-
searched aspect of cancer cachexia.
We observed atrophy in all muscles studied, although
the EDL was considerably more sensitive to wasting than
the SOL. Not only did atrophy occur earlier in the EDL,
but at the ﬁnal time point studied, the EDL had experi-
enced an almost twofold greater relative loss of mass and
pCSA compared to the SOL. This greater sensitivity of
the EDL to wasting is consistent with a previous LLC
study (Busquets et al. 2004) and with other cancer mod-
els, such as the C-26 carcinoma (Diffee et al. 2002;
Acharyya et al. 2004) and Apc
Min/+ mice (Baltgalvis et al.
2008). In human cancer patients, fast muscle ﬁbers have
been reported to undergo more extensive atrophy than
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that are signiﬁcantly different (P-values above lines). Number of SOL and EDL muscles same as in Figures 4 and 5, respectively. Number of DIA
muscle preparations: 10 M and 12 L at 21 days; 11 M and 13 L at 25 days.
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support this ﬁnding as the C57BL/6 mouse SOL and EDL
comprised ~50 and 95% fast myosin, respectively (Agbu-
lut et al. 2003).
Our data reveal that reductions in muscle mass alone
are not the sole explanation for the force deﬁcits that
occur with cachexia. Most notably, both the EDL and the
DIA showed ~20% losses in force per unit pCSA (speciﬁc
force) when tumor growth was extended to 25 days. A
loss in EDL or DIA peak-speciﬁc force in tumor-bearing
mice differs from the ﬁndings of previous studies. This is
most likely because previous work, (1) studied mice with
much lower tumor load than in this study (Murphy et al.
2011), or (2) made their ﬁnal measurements 21–22 days
after tumor inoculation (Gorselink et al. 2006; Aulino
et al. 2010), a time at which we also observed no loss in
speciﬁc force.
Because we used an ex vivo preparation, our ﬁndings
can be attributed directly to the muscle tissue. In con-
trast, functional assays conducted in vivo or in situ can
be impacted by several physiological processes that are
absent or controlled in an ex vivo preparation. These
include neuronal action potential propagation, action
potential propagation across the neuromuscular junction,
and blood ﬂow. Although these other factors may be
important physiological features of cachexia, focusing on
the muscle tissue per se was a priority because our long-
term goal is to understand how cellular mechanisms of
contraction are altered in tumor-bearing animals. An ex
vivo approach also enabled us to study the mechanical
properties of the critically important DIA muscle using
methodology identical to that used for the SOL and
EDL.
It is important to note that the reduction in speciﬁc
force reported here is of sufﬁcient magnitude to be physi-
ologically relevant. Because EDL absolute force dropped
43%, but pCSA only 29%, the loss in speciﬁc force
accounts for ~33% of the total force loss experienced by
the muscle. While we cannot make similar calculations
for the DIA (we are unable to calculate an absolute force
deﬁcit for this muscle because the size of the dissected
muscle strip, and hence its absolute force, is an uncon-
trolled variable), the reduction in speciﬁc force of this
muscle was similar to that of the EDL. A loss of DIA-
speciﬁc force may be a critical factor contributing to respi-
ratory failure in the later stages of cachexia. Conversely,
reversing this loss of speciﬁc force may be an important
intervention for maintaining respiratory function.
The reductions in speciﬁc force reported here suggest a
change in cellular and molecular mechanisms responsible
for force production. Because we studied limb muscles
contralateral to the tumor site, as well as the DIA, these
changes cannot be attributed to regional effects of the
tumor, such as altered blood ﬂow, but instead point to
systemic mechanisms. Tumors secrete factors, or induce
the host to produce factors, that increase protein degrada-
tion in skeletal muscle cells (for review, see (Tisdale
2009). It should be noted that protein degradation in can-
cer cachexia appears to be preferential, with the motor
protein myosin particularly susceptible to loss (Acharyya
et al. 2004; Banduseela et al. 2007). This preferential loss
of myosin, along with gross disorganization of sarcomere
ultrastructure (Banduseela et al. 2007; Aulino et al. 2010),
would all be consistent with a loss of muscle-speciﬁc
force.
In addition to direct loss of contractile protein, several
of the molecules that signal elevated proteolysis in cancer
cachexia, such as TNF-a (Llovera et al. 1998a) and NF-jB
(Cai et al. 2004), have been shown to have depressive
effects on muscle contractility (Wilcox et al. 1994; Reid
et al. 2002; Cai et al. 2004; Hardin et al. 2008). Cachexia
is also associated with elevations in reactive oxygen inter-
mediates (Buck and Chojkier 1996) and above normal
levels of oxidants depress muscle contractility (Andrade
et al. 1998; Prochniewicz et al. 2008). It is important to
note that at least some of the effects of elevated TNF-a
(Reid et al. 2002; Hardin et al. 2008) and reactive oxygen
intermediates (Andrade et al. 1998; Prochniewicz et al.
2008) would be expected to be acute or qualitative, that
is, an immediate, direct impact on cross-bridge function
versus their potential longer term quantitative effects on
cross-bridge number.
It is possible that the transmission of force to the ten-
dons may be impaired in cachexia. Dystrophin, a cyto-
skeletal protein, has been reported to be reduced in
tumor-bearing mice (Acharyya et al. 2005). Dystrophin
is thought to protect the sarcolemma from damage dur-
ing contraction and to assist in transmitting force from
actin ﬁlaments to the extracellular matrix (Petrof et al.
1993; Rybakova et al. 2000). Therefore, a loss of this
protein may contribute to reductions in the force
produced by the muscle–tendon complex. Finally, the
observed loss in speciﬁc force could arise from events
occurring at the tissue level, that is, a shift toward a
relatively greater amount of noncontractile material in
the muscle.
Future studies will need to identify which of the above
mechanisms is responsible for reductions in speciﬁc force.
Expressing force relative to myoﬁbrillar protein content
(Taylor and Kandarian 1994), as suggested by one
reviewer, may be useful in identifying whether changes in
noncontractile components play a role in the loss in spe-
ciﬁc force but this approach cannot distinguish between
normal cross-bridges and cross-bridges that have
impaired function (Faulkner et al. 1999). Likewise, ultra-
structural analyses (Aulino et al. 2010) can quantify a
ª 2013 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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state of those cross-bridges that remain. These and other
biochemical, molecular, and ultrastructural approaches
will need to be combined with single ﬁber functional
assays (Banduseela et al. 2007; Prochniewicz et al. 2008)
in order to identify the mechanisms responsible for the
speciﬁc force losses observed here. Regardless of the
mechanisms involved, the present results demonstrate that
functional deﬁcits in some muscles of tumor-bearing mice
exceed losses in the muscles’ pCSA. Thus, changes in
muscle mass are unlikely to be an appropriate surrogate
measure of muscle function during cachexia, a ﬁnding
that needs to be considered in the design of future experi-
ments.
It should be noted that the tumor-bearing mice in the
present work became subjectively less active as the study
progressed. This raises the possibility that the bone loss
and muscle functional deﬁcits we observed were brought
about by reductions in normal physical activity. In terms
of muscle, this interpretation is opposed by our ﬁnding
that the DIA of 25-day tumor-bearing mice also showed
deﬁcits in speciﬁc force. It therefore seems unlikely that
speciﬁc force deﬁcits can be explained entirely, if at all,
by tumor-induced reductions in the normal physical
activity of the animals. Future studies will need to mea-
sure and systemically manipulate physical activity of
tumor-bearing animals in order to better understand
potential interactions between physical activity, tumor
growth, and bone and muscle physiology.
In summary, we have shown that the LLC model has
no effect on the caloric intake of C57 mice, yet induces
substantial reductions in both their lean and fat mass
compartments. We observed substantial losses in BMD in
tumor-bearing animals and signiﬁcant muscle atrophy
and force deﬁcits in both limb and respiratory muscles.
Muscles comprised predominately of fast ﬁbers showed
more severe forces losses as well as an additional loss in
speciﬁc force, suggesting that cellular mechanisms of force
production and/or transmission are impacted by cachexia.
These deﬁcits in BMD and muscle-speciﬁc force were not
physiologically trivial: BMD fell to a level similar to that
reported after prolonged nonweight bearing or ovariec-
tomy (Kim et al. 2013; Spatz et al. 2013) while the losses
in muscle-speciﬁc force accounted for approximately one-
third of the loss in total muscle force production. The
LLC model described here induces substantial alterations
to muscle and bone and may be a useful tool for under-
standing the musculoskeletal deterioration that occurs in
human cancer patients.
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